FDA Approval of Crysvita® for X-linked Hypophosphatemia (XLH)

Dr. Emil D. Kakkis, M.D., Ph.D., CEO and President of Ultragenyx discusses the recently FDA approved (April 2018) Crysvita® (burosumab-twza) for the treatment of X-linked hypophosphatemia (XLH), a rare skeletal disorder and Ultragenyx’s continued commitment to researching treatments for rare diseases like XLH.

Guest Bio: Dr. Emil Kakkis is currently the Founder and Chief Executive Officer of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company committed to the development of novel therapies for rare and ultra-rare diseases, based in Northern California. Dr. Kakkis has worked in rare diseases for 27 years as an academic professor, biotechnology and nonprofit foundations. He spent 11 years at BioMarin, in the role of Chief Medical Officer. In addition, Dr. Kakkis founded and is a current board member of the EveryLife Foundation for Rare Diseases, a non-profit organization dedicated to the acceleration of biotech innovation for rare diseases through practical and scientifically sound improvements to development strategies, regulatory policy and the law.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.